ClinicalTrials.gg
RecruitingNCT06210009Updated Jan 13, 2026

Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease

An interventional study of DASH-Style Diet and Western-Style Diet in Kidney Stone, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 19 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Calculi by University of Alabama at Birmingham — 6 open to participants now, 12 under way, none of them phase 3. Kidney Calculi · University of Alabama at Birmingham.

Planned enrollment
7th of 17
48 · median 40
Started
2025
with 2 others
No phase
17 of 17
6 open now
Primary completion
2027-08
later than 5 of 11 live
Registered
14th of 17
by date

Among the 17 studies in Kidney Calculi by University of Alabama at Birmingham, this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 17 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 14th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 17 studies in Kidney Calculi by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Calculi by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The true capacity for a healthy diet to improve urinary stone risk factors is not well-defined. The objective of this study is to measure the effect of adopting a healthy dietary pattern on kidney stone disease (KSD) risk. The working hypothesis is that a Dietary Approaches to Stop Hypertension (DASH)-style diet will improve 24-hour urine stone risk parameters. The approach to testing this hypothesis will be to randomize participants with KSD to a standardized DASH-style vs. Western-style diet for one week. The Bionutrition Unit of the Center for Clinical and Translational Science will provide all meals to participants. The rationale for this study is that by measuring the effect of a DASH-style diet on urinary stone risk parameters, a benchmark for future real-world, implementation studies will be established. Based on available evidence, this will be the first controlled diet study to assess the DASH dietary pattern for improving urinary stone risk parameters.

03

Conditions studied

  • Kidney Stone

Browse trials for

Keywords

  • DASH diet
  • Western diet
04

Who can participate

Ages eligible
19 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Birmingham, AL area participants of the Coronary Artery Risk Development in Young Adults (CARDIA) study OR patients of the University of Alabama at Birmingham/Kirklin Clinic
  • Self-reported, documented, and/or prior imaging-based diagnosis of kidney stone disease
  • Age 19-89
  • Any sex
  • Any race
  • Able to provide
  • Willing to perform 24-hour urine collections
  • Willing to consume meals prepared by Bionutrition Unit
  • No food allergies/intolerance to any of the foods in the study menus
  • Willing to stop for 7 days before and during study: Multivitamins and/or Dietary supplements (including calcium and vitamin C)

Exclusion criteria

Exclusion Criteria:

  • Dialysis
  • Kidney transplant recipient
  • Estimated (eGFR) \<60 ml/min/1.73m2 based on historical laboratory measurements
  • Renal tubular acidosis
  • Current use of acetazolamide, topiramate, or zonisamide
  • Primary hyperparathyroidism or history of parathyroidectomy
  • Hyperthyroidism
  • Sarcoidosis
  • Primary hyperoxaluria
  • Cystinuria
  • Nephrotic syndrome
  • Malabsorptive conditions including inflammatory bowel disease or history of malabsorptive surgery (e.g., Roux-en-Y gastric bypass, small bowel resection)
  • Urinary retention requiring catheterization
  • Urinary diversion
  • Pregnancy
  • Breastfeeding
  • treated in the past 12 months other than non-melanoma skin cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    DASH-Style Diet

    For seven days, participants will consume a diet characterized by higher intake of fruits, vegetables, and low-fat dairy, in addition to whole grains, poultry, fish, and nuts, but smaller amounts of red meat, sweets, and sugar-containing beverages.

    Other: DASH-Style Diet

  • Other
    Western-Style Diet

    For seven days, participants will consume a diet characterized by characterized by higher intake of red meat, sweets, and items containing added sugar, processed starches, and seed oils, in addition to lower intake of fruits, vegetables, and low-fat dairy.

    Other: Western-Style Diet

Interventions

  • OtherDASH-Style Diet

    Participants will be randomized to a DASH-style diet

  • OtherWestern-Style Diet

    Participants will be randomized to a Western-style diet

06

What researchers measure

Primary outcomes

  1. Difference between the two arms in supersaturation of calcium oxalate

    Supersaturation of calcium oxalate is an index reflecting the propensity for the formation and growth of the most common stone type (calcium oxalate), which is calculated using excretion rates including urinary volume, calcium, citrate, and oxalate.

    Time frame: Days 6-7 of the assigned intervention

Secondary outcomes

  1. Difference between the two arms in supersaturation of calcium oxalate between the baseline and intervention periods

    This secondary outcome will be calculated using a difference in differences approach.

    Time frame: Days 6-7 of the assigned intervention

  2. Difference between the two arms in supersaturation of uric acid

    Supersaturation of uric acid is an index reflecting the propensity for the formation and growth of uric acid stones.

    Time frame: Days 6-7 of the assigned intervention

  3. Difference between the two arms in supersaturation of calcium phosphate

    Supersaturation of calcium phosphate is an index reflecting the propensity for the formation and growth of calcium phosphate stones.

    Time frame: Days 6-7 of the assigned intervention

  4. Difference between the two arms in urine volume

    Low urine volume is a stone risk factor.

    Time frame: Days 6-7 of the assigned intervention

  5. Difference between the two arms in urine calcium

    High urine calcium is a stone risk factor.

    Time frame: Days 6-7 of the assigned intervention

  6. Difference between the two arms in urine oxalate

    High urine oxalate is a stone risk factor.

    Time frame: Days 6-7 of the assigned intervention

  7. Difference between the two arms in urine citrate

    Low urine citrate is a stone risk factor.

    Time frame: Days 6-7 of the assigned intervention

  8. Difference between the two arms in urine uric acid

    High urine uric acid is a stone risk factor.

    Time frame: Days 6-7 of the assigned intervention

  9. Difference between the two arms in urine pH

    Urine pH can influence stone formation and growth.

    Time frame: Days 6-7 of the assigned intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 31 months is close to that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 18, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06210009
Responsible party
Joseph Crivelli (Assistant Professor of Urology, University of Alabama at Birmingham) — Principal investigator
First posted
Jan 18, 2024
Start date
Jan 6, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Joseph Crivelli, MD
Contact
crivelli@uab.edu
205-996-8765

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion